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Background
Cancer progression is associated with a severe impairment
of anti-tumor immune responses. The accumulation of
peripheral blood CD14+HLA-DRlo/- monocytic MDSCs
has been identified as a prognostic factor in advanced
stage melanoma patients. These cells suppress T cell func-
tions ex vivo and reversely correlate with the frequencies
of antigen-specific T cells in patients. However, the precise
mechanistic basis underlying this effect is unclear, particu-
larly with regard to how MDSCs are induced and how
they could limit functions of NK cells in cancer patients.
Methods
The effects of tumor-derived factors in inducing phenoty-
pic and functional alternations on healthy human mono-
cytes or CD34+ hematopoietic stem cells (HSCs) were
analyzed in vitro, by co-culturing monocytes with early-
passage tumor cells or addition of tumor-conditioned med-
ium, respectively. Suppression of T or NK cell activity by
MDSC-like cells was compared with that of freshly isolated
CD14+HLA-DRlow/- monocytic MDSCs (moMDSCs)
from patients with melanoma. In addition, to explore the in
vivo relevance of targeting PGE2 to reduce MDSC expan-
sion, we established a murine model, where tumor cells
were disabled from cyclooxygenase-2 (COX-2) production
and in vivo NK cytotoxicity was evaluated by live imaging.
Results
We recently demonstrated that tumor-derived factors pro-
moted monocytes to acquire an MDSC-like phenotype
and suppressive functions of T cells via COX-2/PGE2
pathway (Mao et al. Cancer Res., 2013). Moreover, tumor-
derived factors resulted in a retention of c-kit+ cells
(p < 0.05) and hampered differentiation of CD34+ HSCs
to functional myeloid cells. As a result, these cells showed
decreased ability to stimulate T cells to proliferate and
produce IFNg (p < 0.05). In patients with melanoma,
freshly isolated CD14+HLA-DRlow/- moMDSCs strongly
suppressed cytotoxicity (p < 0.05) and production of IFNg
(p < 0.01) by NK cells, through production of TGFb
(p < 0.05). In vitro, binding of PGE2 to EP2 or EP4 recep-
tors on monocytes activated the p38MAPK/ERK pathway
and resulting in elevated secretion of TGFb (p < 0.05) and
reduced NK cell cytotoxicity (p < 0.01). Importantly, silen-
cing COX-2 in 4T1 tumor cells reduced the frequency of
splenic CD11b+Gr1+ MDSCs (p < 0.01), resulting in con-
comitant improved in vivo clearance of NK-sensitive
YAC-1 target cells (p < 0.05).
Conclusions
Collectively, our results reveal a direct involvement and
molecular machinery of tumor-derived factors, in particu-
lar PGE2, in inducing immature phenotype and stimulating
suppressive functions from MDSCs. Therefore, combining
COX-2 inhibitors with immunotherapy may result to a
favorable clinical outcome in patients with cancer.
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